Nicotinamide adenine dinucleotide (NAD), a prominent member of the pyridine nucleotide family, plays a pivotal role in cell-oxidation protection, DNA repair, cell signalling and central metabolic pathways, such as beta oxidation, glycolysis and the citric acid cycle. In particular, extracellular NAD + has recently been demonstrated to moderate pathogenesis of multiple systemic diseases as well as aging. Herein we present an assaying method, that serves to quantify extracellular NAD + in human heparinised plasma and exhibits a sensitivity ranging from the low micromolar into the low nanomolar domain. The assay achieves the quantification of extracellular NAD + by means of a two-step enzymatic cycling reaction, based on alcohol dehydrogenase. An albumin modified revised simulated body fluid was employed as standard matrix in order to optimise enzymatic activity and enhance the linear behaviour and sensitivity of the method. In addition, we evaluated assay linearity, reproducibility and confirmed long-term storage stability of extracellular NAD + in frozen human heparinised plasma. In summary, our findings pose a novel standardised method suitable for high throughput screenings of extracellular NAD + levels in human heparinised plasma, paving the way for new clinical discovery studies.
Introduction
Nicotinamide adenine dinucleotide (NAD) is a pyridine dinucleotide omnipresent in all living cells either in oxidised (NAD + ), or reduced (NADH) form, whose ratio dictates the intracellular redox status and thus stipulates the overall cellular metabolic state 1, 2 . Extracellular NAD + (eNAD + ) was shown to exhibit important secondary messenger properties and acts to induce intracellular calcium release, thereby mediating lymphocyte chemotaxis 3 . Interestingly, eNAD + is known to be the result of either lytic release from injured tissue or non-lytic release mechanisms through pore forming proteins like connexin 43 (Cx43) hemichannels and is thus hypothesised to mediate immune response and organ function by means of paracrine signalling [4] [5] [6] . erapeutic applications of eNAD + have been subject to extensive testing in murine models, with striking ndings demonstrating anti-aging, regenerative and highly immunomodulatory traits 7, 8 . For instance, T et al., 2014 discovered that the systemic administration of b -NAD + did not only block autoimmune encephalomyelitis induced paraplegia, but reversed disease progression through remyelination and neuroregeneration 9 . Furthermore, eNAD + induced regulatory T cell dierentiation, promoting allogra survival in a murine skin transplantation model with implications for concepts of alloimmunity and inammatory diseases 10 . However, a signicant lack of medical translation towards the study of eNAD + in human disease is apparent.
In fact, the measurement of eNAD + in dierent bodily compartments is challenging due to vast concentration variations. In human erythrocytes, intracellular NAD + (iNAD + ) was determined to be in the range of 10M -40M, whilst eNAD + in pig plasma was found at a fraction of this concentrations, namely 240nM -290nM [11] [12] [13] . erefore, analytical tests have to be inherently robust and span vastly dierent concentration ranges. High performance liquid chromatography (HPLC) NAD + analysis methods usually require any and all samples to be internally spiked with NAD + and have struggled to quantify NAD due to signal masking and ionisation suppression, especially when followed by ultraviolet-visible (HPLC-UV) spectroscopic quantication 14 . However, HPLC methods followed by mass spectrometry (HPLC-MS), and especially tandem mass spectrometry (HPLC-MS/MS), have managed to achieve remarkable sensitivity and specicity for iNAD + thanks to their ability to separate the respective metabolites through elution with highly specialised columns and successively combining the relaxation time of specic metabolites with their mass spectrum 
